BlaidsX Neuro vs EarCentric EX2

The BlaidsX Neuro is a mid-priced OTC hearing aid that earns a B grade with a SoundScore of 3.3/5 in our lab testing. At $799 for this behind-the-ear, rechargeable device, it sits in a competitive price bracket where several higher-performing alternatives exist. In our testing, the Neuro shows a mixed performance profile. Its standout strength is speech clarity in quiet environments, scoring 3.3/5—a solid result that's 0.54 points above the OTC category average. Feedback handling is excellent at 5.0/5, meaning users can expect stable performance without whistling or squealing during normal use. However, the device struggles in more challenging areas: speech in noise scores just 1.0/5 (0.48 points below category average), and music streaming registers at 0.0/5, significantly below the already-modest category average. Own-voice comfort is another weak point, scoring 1.7/5—well below the category average by 0.81 points. This may result in an unnatural sound of one's own voice during conversations. The tuned fit improves the overall score modestly from 3.3 to 3.5, primarily through enhanced feedback stability, though own-voice comfort decreases with the more occluding tulip dome coupling. The BlaidsX Neuro may suit users who primarily need help hearing speech in quieter settings and prioritize feedback-free performance. However, those who frequently encounter noisy environments, stream music, or have higher expectations for overall sound quality should consider alternatives in this price range, several of which score substantially higher in our testing.

The EarCentric EX2 is a behind-the-ear prescription hearing aid priced at $218, positioning it as a budget-friendly option in the prescription category. In HearAdvisor's lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking #35 of 39 prescription hearing aids tested. This 2021 release demonstrates mixed performance across key metrics. Its standout strength is feedback handling, scoring an excellent 4.7/5—essentially matching the category average and indicating reliable stability during movement. However, speech performance is a significant weakness: speech in quiet scores just 1.0/5 (2.40 points below the category average of 3.40), and speech in noise scores 1.0/5 (1.11 points below average). These low absolute scores suggest limited audibility enhancement in our standardized test conditions. Own-voice comfort scores 2.3/5, which is mixed in absolute terms and 0.40 points below the category average. Music streaming scored 0.0/5, indicating this device is not suited for audio entertainment purposes. The EarCentric EX2 may appeal to budget-conscious consumers who prioritize cost over performance, but alternatives exist at similar or lower price points with stronger test results. The RxEars Rxi, available in the same price range, scored 4.07/5 in our testing. Consumers seeking entry-level amplification should weigh the significant speech clarity limitations against the low purchase price.